137 related articles for article (PubMed ID: 35096582)
1. Recurrent Gallbladder Carcinoma With pMMR/MSS Achieved a Complete Response Following Camrelizumab Combined With Apatinib: A Case Report.
Zhong L; Liu X; Li Z; Zhang X; Wang Y; Peng W
Front Oncol; 2021; 11():783158. PubMed ID: 35096582
[TBL] [Abstract][Full Text] [Related]
2. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
[TBL] [Abstract][Full Text] [Related]
3. Rectosigmoid-Junction Squamous Cell Carcinoma With pMMR/MSS Achieved a Partial Response Following PD-1 Blockade Combined With Chemotherapy: A Case Report.
He Y; Wang L; Li X; Zhang T; Song T; Zhang J; Yu Y; Chen S; Song H
Front Oncol; 2021; 11():596342. PubMed ID: 34113555
[TBL] [Abstract][Full Text] [Related]
4. Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report.
Liu Y; Du J; Zhang P; Meng W; Xiao H
Front Oncol; 2023; 13():1051786. PubMed ID: 36969074
[TBL] [Abstract][Full Text] [Related]
5. Complete response to immunotherapy combined with an antiangiogenic agent in multiple hepatic metastases after radical surgery for advanced gallbladder cancer: a case report.
Rao J; Xia J; Yang W; Wu C; Sha B; Zheng Q; Cheng F; Lu L
Ann Transl Med; 2020 Dec; 8(23):1609. PubMed ID: 33437808
[TBL] [Abstract][Full Text] [Related]
6. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
[TBL] [Abstract][Full Text] [Related]
7. PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report.
Yang J; Xing P; Kong Y; Xu M; Zhang L
Front Oncol; 2023; 13():1078915. PubMed ID: 37188188
[TBL] [Abstract][Full Text] [Related]
8. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of pMMR MSS IVB Colorectal Cancer Using Anti-VEGF and Anti-PD-1 Therapy in Combination of Gut Microbiota Transplantation: A Case Report.
Cheng X; Li X; Yang X; Fang S; Wang Z; Liu T; Zheng M; Zhai M; Yang Z; Shen T
Cureus; 2023 Jul; 15(7):e42347. PubMed ID: 37621810
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Complete pathological remission of human chorionic gonadotrophin-producing gallbladder carcinoma with multiple liver metastases after treatment with chemotherapy plus an immune checkpoint inhibitor.
Wang Q; Mu Y; Ji S; Liu Y; Lou Y; Wei S; Dong X; Zhang B
Front Immunol; 2023; 14():1173520. PubMed ID: 37841278
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study.
Li RR; Yin XL; Zeng DY; Shao FJ; Yamamoto S; Liu W; Liu ZY
Ann Transl Med; 2022 Aug; 10(16):880. PubMed ID: 36111036
[TBL] [Abstract][Full Text] [Related]
12. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade.
Sui M; Li Y; Wang H; Luo Y; Wan T; Wang X; Hu B; Cheng Y; Lv X; Xin X; Xu Q; Wang G; Lu S
J Immunother Cancer; 2019 May; 7(1):125. PubMed ID: 31064408
[TBL] [Abstract][Full Text] [Related]
13. Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study.
Yan Z; Ma J; Yao S; Yao Z; Wang H; Chu J; Zhao S; Liu Y
Front Immunol; 2021; 12():727464. PubMed ID: 34899689
[TBL] [Abstract][Full Text] [Related]
14. Alteration in the Immune Microenvironment Based on APC Status in MSS/pMMR Colon Cancer.
Lin H; Cao B
Dis Markers; 2022; 2022():3592990. PubMed ID: 35937946
[TBL] [Abstract][Full Text] [Related]
15. Acute inflammatory reaction during anti-angiogenesis therapy combined with immunotherapy as a possible indicator of the therapeutic effect: Three case reports and literature review.
Lei Y; Lin L; Cheng S; Shao Q; Ding C; Zuo R; Chen W; Liao Q; Liu G
Front Oncol; 2023; 13():1072480. PubMed ID: 37124541
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study.
Li J; Cong L; Liu J; Peng L; Wang J; Feng A; Yue J; Li L; Wang X; Wang X
Front Oncol; 2020; 10():594125. PubMed ID: 33282742
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report.
Lin S; Chen W; Chen Z; Liang J; Zhong L; Jiang M
Ann Transl Med; 2022 Mar; 10(6):380. PubMed ID: 35433988
[TBL] [Abstract][Full Text] [Related]
19. Successful response to camrelizumab in metastatic bladder cancer: A case report.
Xie C; Yuan X; Chen SH; Liu ZY; Lu DL; Xu F; Chen ZQ; Zhong XM
World J Clin Cases; 2022 Jan; 10(1):254-259. PubMed ID: 35071525
[TBL] [Abstract][Full Text] [Related]
20. Case report: Preliminary response to tislelizumab plus S-1 in patients with metastatic gallbladder carcinoma: A report of five cases and a literature review.
Zhang Y; Liu Y; Liu J; Liu T; Xiong H; Li W; Fu X; Zhou F; Liao S; Fang L; Liang B
Front Immunol; 2023; 14():1144371. PubMed ID: 37020545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
